Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single-cell RNA-sequencing

Jie Li1, Yaping Long2, Tao Wang3

  • 1Department of Pathology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.

PubMed
Abstract

Insights

Tracheal adenoid cystic carcinoma (TACC) may originate from ciliated epithelial cells, with impaired immune cell function contributing to its progression. Targeting the MIF-CD74 pathway offers potential therapeutic strategies for this rare cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Tracheal adenoid cystic carcinoma (TACC) is a rare cancer with high recurrence and metastasis rates.
  • Limited understanding of TACC's molecular characteristics hinders effective treatment.
  • Single-cell RNA sequencing (scRNA-seq) offers a novel approach to analyze TACC.

Purpose of the Study:

  • To conduct an in-depth molecular analysis of TACC using scRNA-seq.
  • To identify key cell populations and molecular drivers in TACC.
  • To provide evidence for developing new TACC treatment strategies.

Main Methods:

  • Single-cell RNA sequencing (scRNA-seq) of peripheral blood, tumor, and adjacent tissues from TACC patients.
  • Bioinformatic analysis to identify cell clones and molecular characteristics.
  • Fluorescent multiplex immunohistochemistry (mIHC) for marker validation.

Main Results:

  • scRNA-seq identified epithelial, immune, and stromal cell populations in TACC.
  • Ciliated epithelial cells expressing stem-cell markers may be the origin of TACC.
  • Impaired natural killer (NK) and cytotoxic T cell function observed.
  • A distinct malignant mesothelial cell subgroup identified, interacting with macrophages via the MIF-(CD74 + CXCR4 or CD44) pathway.
  • High density of CD68+CD74+ cells near Vimentin+PANCK+ cells confirmed by mIHC.

Conclusions:

  • TACC may originate from ciliated epithelial cells.
  • Abnormal gene expression and immune cell dysfunction are critical in TACC development and progression.
  • Targeting MIF-CD74 signaling pathways presents a promising therapeutic avenue for TACC.